The stock price of Genolution, a green bio-specialized company listed on the KOSDAQ, is strong in early trading on the 25th. The buying momentum is attributed to the news of its technological achievement in suppressing the deadly nosema disease in bees being published in an international academic journal.
As of 9:18 a.m. on this day, Genolution's stock price is trading at 2,665 won, up 330 won (14.13%) compared to the previous trading day.
On this day, Genolution announced that it has published its results of developing ribonucleic acid (RNA) interference technology to suppress the microbial pathogen Vairimorpha ceranae, which causes nosema disease, in the international journal CBTA (Chemical and Biological Technologies in Agriculture). Nosema disease is an infectious disease that impairs bees' ability to fly.
Genolution explained that it designed double-stranded RNA (dsRNA) targeting specific genes to verify the effect of suppressing nosema infections in bees. The company emphasized that it has significantly increased the feasibility of realizing next-generation pest control strategies.
A Genolution official noted, "As a result of this paper's publication, we are ramping up our research and development to conduct clinical trials within the next three years, and we will introduce next-generation eco-friendly pest control solutions not only for bees but also for various agricultural pests in the future."